Revolution Medicines, Inc. (RVMD)

NASDAQ: RVMD · Real-Time Price · USD
44.93
-1.50 (-3.23%)
At close: Dec 12, 2024, 4:00 PM
44.94
+0.01 (0.02%)
After-hours: Dec 12, 2024, 6:45 PM EST
-3.23%
Market Cap 7.56B
Revenue (ttm) 742,000
Net Income (ttm) -567.06M
Shares Out 168.22M
EPS (ttm) -3.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,243,695
Open 46.03
Previous Close 46.43
Day's Range 44.91 - 46.82
52-Week Range 25.58 - 62.40
Beta 1.40
Analysts Strong Buy
Price Target 62.77 (+39.71%)
Earnings Date Nov 6, 2024

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2020
Employees 378
Stock Exchange NASDAQ
Ticker Symbol RVMD
Full Company Profile

Financial Performance

In 2023, Revolution Medicines's revenue was $11.58 million, a decrease of -67.27% compared to the previous year's $35.38 million. Losses were -$436.37 million, 75.5% more than in 2022.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $62.77, which is an increase of 39.71% from the latest price.

Price Target
$62.77
(39.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million

7 days ago - GlobeNewsWire

Revolution Medicines: Risky Buy On Recent Share Price Dip

Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDA...

8 days ago - Seeking Alpha

Top 3 Health Care Stocks That Could Blast Off In December

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ELANSHC
8 days ago - Benzinga

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

9 days ago - GlobeNewsWire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

10 days ago - GlobeNewsWire

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial

10 days ago - GlobeNewsWire

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

15 days ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript

5 weeks ago - Seeking Alpha

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile

5 weeks ago - GlobeNewsWire

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou...

5 weeks ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

6 weeks ago - GlobeNewsWire

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC

6 weeks ago - GlobeNewsWire

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October ...

7 weeks ago - GlobeNewsWire

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

7 weeks ago - GlobeNewsWire

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking ...

2 months ago - GlobeNewsWire

Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript

Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairm...

4 months ago - Seeking Alpha

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

4 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

4 months ago - GlobeNewsWire

Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter

As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: AVAHFULC
5 months ago - Benzinga

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in prec...

5 months ago - GlobeNewsWire

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

5 months ago - GlobeNewsWire

Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer...

6 months ago - GlobeNewsWire

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers...

7 months ago - GlobeNewsWire

Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers...

8 months ago - GlobeNewsWire

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology...

8 months ago - GlobeNewsWire